ArticleOncotarget2017
Clinical role and biological function of CDK5 in hepatocellular carcinoma: A study based on immunohistochemistry, RNA-seq and
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- mRNA Isoforms and Variants in Health and Disease.International journal of molecular sciences · 2025Review
- CDK5: an oncogene or an anti-oncogene: location location location.Molecular cancer · 2023Review
- Tolerance of repeated toxic injuries of murine livers is associated with steatosis and inflammation.Cell death & disease · 2023Article
- The cyclin dependent kinase inhibitor Roscovitine prevents diet-induced metabolic disruption in obese mice.Scientific reports · 2021Article
- Elevated CDK5R1 predicts worse prognosis in hepatocellular carcinoma based on TCGA data.Bioscience reports · 2021Article
- CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.Frontiers in oncology · 2021Review
- Lnc-ATG9B-4 aggravates progress of hepatocellular carcinoma through cell proliferation and migration by upregulating CDK5.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance.International journal of molecular medicine · 2020Article
- Targeting the cyclin-dependent kinase 5 in metastatic melanoma.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the clinical role and biological function of cyclin-dependent kinase 5 (CDK5) in hepatocellular carcinoma (HCC), 412 surgically resected tissue samples (HCC, n=171; non-HCC=241) were obtained and analyzed with immunohistochemistry. The diagnostic and prognostic values of CDK5 expression levels in HCC were clarified. Moreover, RNA-seq data or microarray datasets from The Cancer Genome Atlas (TCGA) (HCC, n=374; normal, n=50) or other public databases (HCC, n=1864; non-tumor=1995) regarding CDK5 in HCC were extracted and examined. Several bioinformatic methods were performed to identify CDK5-regulated pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.